January 10, 2026
View Full PaperSGLT2 inhibitors: Do they have antiarrhythmic properties?
Key Result
SGLT2 inhibitors may reduce new-onset and recurrences of atrial fibrillation in patients with heart failure or chronic kidney disease, but evidence for ventricular arrhythmias is weak.
Key Points
- This research investigates whether SGLT2 inhibitors have antiarrhythmic effects in patients with cardiac conditions.
- Reviewed clinical studies and meta-analyses of SGLT2 inhibitors
- Assessed the incidence of atrial fibrillation and ventricular arrhythmias
- Explored the mechanisms behind antiarrhythmic effects
- SGLT2 inhibitors significantly reduce new-onset atrial fibrillation in patients with heart failure and chronic kidney disease.
- Evidence for a reduction in ventricular arrhythmias and sudden cardiac arrest is inconclusive.
- The exact mechanism of antiarrhythmic effects is still uncertain and requires further research.
Structured PICO
Do SGLT2 inhibitors have antiarrhythmic properties in patients with T2D, HF, or CKD?
P
Population
Patients with type 2 diabetes (T2D), heart failure (HF), or chronic kidney disease (CKD)
I
Intervention
SGLT2 inhibitors
SGLT2 inhibitors appear to reduce atrial fibrillation risk in HF or CKD patients, though evidence for ventricular arrhythmias remains weak and hypothesis-generating.
Main Result
Absolute Event Rate: 0% vs 0%
Abstract
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent the cornerstone of therapy in patients with type 2 diabetes (T2D), heart failure (HF), or chronic kidney disease. These patients present a high risk of cardiac arrhythmias, particularly when these comorbidities coexist. In experimental models SGLT2i exert antiarrhythmic effects and clinical studies and meta-analyses strongly suggest that they reduce new-onset and recurrences of atrial fibrillation in patients with HF or CKD irrespective of the diabetic status. Although some trials and meta-analyses suggest that SGLT2i could decrease the risk of ventricular arrhythmias and sudden cardiac arrest, the evidence is weak, and their potential remains to be confirmed. Thus, clinical evidence so far should be considered as hypothesis-generating. Although the exact mechanism underlying their antiarrhythmic effects remains uncertain and much research is needed, multiple direct cardiac and extracardiac effects may be involved. They improve cardiac electrical (via changes in ion channels and transporters; maintenance of Na